Centre for Cancer Research - Theses
Now showing items 1-6 of 6
Investigation of the tumour microenvironment of prostate cancer
One in seven men in Australia is at risk of developing prostate cancer before the age of 75. This disease is a leading cause of male death worldwide, with a mortality rate of 62 men per 100,000. Treatments for prostate ...
Immune markers to predict response to neoadjuvant chemoradiotherapy and identifying methods to incorporate immunotherapy in locally advanced rectal cancer
The standard of care for locally advanced rectal cancer (T3-4 +/- N+) is neoadjuvant chemoradiotherapy (CRT) followed by total mesorectal excision (TME). However, this has been challenged recently with increasing interest ...
Interplay between MDM4 and P53 in breast cancer
Breast cancer (BC) is one of the most prevalent cancer types and second leading cause of cancer death among Australian women. BC is a genetically heterogeneous disease, divided into sub-types that differ in their aggressiveness, ...
Novel strategies to enhance the therapeutic efficacy of chimeric antigen receptor T cell therapy against solid cancer
Adoptive cell therapy using chimeric antigen receptor (CAR) T cells has shown great success in haematological malignancies, leading to recent approval of two CD19-specific CAR T cell products by the Food and Drug Administration ...
Tumour immune microenvironment, genomewide copy number aberrations and their interactions in malignant pleural mesothelioma
Malignant pleural mesothelioma (MPM) is a rare but deadly malignancy. Despite predictions, worldwide incidences have not significantly diminished and available therapeutic modalities have failed to improve outcomes. There ...
Reducing outcome disparities for rural Victorians with colorectal cancer: understanding pathways to treatment and informing policy.
In Victoria, rural patients with colorectal cancer have poorer outcomes than urban counterparts. To date, research and policy initiatives have focused on addressing potential variation in cancer treatment. However, ...